 This study investigates the use of a novel nanovector system to target tumours and enhance the efficacy of immunotherapy. The nanovectors contain two components, a TGF-beta inhibitor to reduce tumour fibrosis and a photosensitising agent to increase the number of T lymphocytes within the tumour. Additionally, the nanovectors are equipped with a GD-celleted PPA payload, which allows for simultaneous imaging-guided photodynamic therapy. Finally, the nanovectors are also armed with a bromidomain-containing protein for inhibitor to prevent adaptive immune resistance. This study demonstrates the potential of combining multiple modalities into one single vector to improve the effectiveness of immunotherapies for immune-excluded tumours.